Is P2Y12 inhibitor therapy associated with an increased risk of cancer?

Area of Science:

• Cardiovascular Medicine
• Oncology
• Pharmacology

Background:

• Antiplatelet therapy, including P2Y12 inhibitors, is standard for cardiovascular disease.
• Growing interest exists regarding a potential link between P2Y12 inhibitor use and solid cancer risk.
• This concern emerged from FDA reviews of TRITON-TIMI 38 and DAPT trials, noting higher cancer incidence with potent P2Y12 inhibitors and prolonged dual antiplatelet therapy (DAPT).

Purpose of the Study:

• To review current evidence on the association between P2Y12 inhibitor therapy and cancer risk.
• To discuss the clinical implications of these findings for patient management.
• To explore basic research investigating the interplay between P2Y12 inhibition and cancer.

Main Methods:

• Review of existing randomized controlled trials (TRITON-TIMI 38, DAPT trial).
• Analysis of subsequent studies, meta-analyses, and clinical guidelines (e.g., European Society of Cardiology).
• Inclusion of findings from basic research on P2Y12 inhibition and cancer.

Main Results:

• A higher risk of cancer was predominantly observed with newer, more potent P2Y12 inhibitors.
• The risk was particularly noted in the context of prolonged dual antiplatelet therapy (DAPT).
• Current guidelines allow for prolonged DAPT based on balancing ischemic versus bleeding risks.

Conclusions:

• The potential for P2Y12 inhibitors to increase cancer risk warrants careful consideration.
• Clinical decisions regarding prolonged DAPT should weigh the benefits against potential cancer risks.
• Further research is needed to fully elucidate the mechanisms and clinical significance of this association.